Identification of subgroups of Schizophrenia patients with changes in either immune or growth factor and hormonal pathways

Schizophrenia Bulletin

Volumn 40, Issue 4, 2014, Pages 787-795

  Schwarz, Emanuel ^a   Van Beveren, Nico J M ^b   Ramsey, Jordan ^a   Leweke, F Markus ^c,d,e   Rothermundt, Matthias ^e   Bogerts, Bernhard ^f   Steiner, Johann ^f   Guest, Paul C ^a   Bahn, Sabine ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

diagnosis; growth factors; immune factors; molecular profiling; schizophrenia; subtypes

Indexed keywords

ADIPONECTIN; AMPHIREGULIN; ANGIOPOIETIN 2; ANGIOTENSINOGEN; ANTIBODY; CD40 LIGAND; ENDOTHELIN 1; FAS LIGAND; GAMMA INTERFERON; GROWTH FACTOR; HORMONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; SIGNAL PEPTIDE;

ADULT; ARTICLE; BRIEF PSYCHOTIC DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DELUSIONAL DISORDER; FEMALE; HEBEPHRENIA; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; REPRODUCIBILITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; CASE CONTROL STUDY; CLASSIFICATION; IMMUNOLOGY; METABOLISM; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HORMONES; HUMANS; IMMUNOASSAY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84902580183     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt105     Document Type: Article

References (41)

1. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry. 2000;57:637-648.
2. Insel TR. Rethinking schizophrenia. Nature. 2010;468: 187-193.
3. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol. 2011;93:23-58.
4. Van Winkel R, Esquivel G, Kenis G, et al. REVIEW: genome-wide fndings in schizophrenia and the role of gene-environment interplay. CNS Neurosci Ther. 2010;16: e185-e192.
5. Carter CJ. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligoden-drocyte viability. Schizophr Res. 2006;86:1-14.
6. Guest PC, Martins-de-Souza D, Vanattou-Saifoudine N, Harris LW, Bahn S. Abnormalities in metabolism and hypothalamic-pituitary-adrenal axis function in schizophrenia. Int Rev Neurobiol. 2011;101:145-168.
7. Drexhage RC, Weigelt K, van Beveren N, et al. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int Rev Neurobiol. 2011;101:169-201.
8. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23:649-659.
9. Müller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010;121:118-124.
10. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138-149.
11. Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007;12:206-220.
12. Korver-Nieberg N, Quee PJ, Boos HB, Simons CJ; GROUP. The validity of the DSM-IV diagnostic classifcation system of non-affective psychoses. Aust N Z J Psychiatry. 2011;45: 1061-1068.
13. Tsuang MT. Heterogeneity of schizophrenia. Biol Psychiatry. 1975;10:465-474.
14. Walker E, Kestler L, Bollini A, Hochman KM. Schizophrenia: etiology and course. Annu Rev Psychol. 2004;55:401-430.
15. Domenici E, Willé DR, Tozzi F, et al. Plasma protein bio-markers for depression and schizophrenia by multi analyte profling of case-control collections. PLoS One. 2010;5:e9166.
16. Schwarz E, Guest PC, Rahmoune H, et al. Identifcation of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012;17:494-502.
17. Drexhage RC, Knijff EM, Padmos RC, et al. The mononu-clear phagocyte system and its cytokine infammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother. 2010;10:59-76.
18. van Beveren NJ, van der Spelt JJ, de Haan L, Fekkes D. Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol. 2006;16:469-480.
19. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 2011;16:960-972.
20. Guest PC, Schwarz E, Krishnamurthy D, et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology. 2011;36:1092-1096.
21. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000;155:945-959.
22. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profles in acute myeloid leukemia. N Engl J Med. 2004;350:1617-1628.
23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
24. Bossuyt PM, Reitsma JB; Standards for Reporting of Diagnostic Accuracy. The STARD initiative. Lancet. 2003;361:71.
25. Mizuno M, Sotoyama H, Narita E, et al. A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by stri-atal administration of epidermal growth factor. J Neurosci. 2007;27:10116-10127.
26. Pillai A, Dhandapani KM, Pillai BA, Terry AV Jr, Mahadik SP. Erythropoietin prevents haloperidol treatment-induced neuronal apoptosis through regulation of BDNF. Neuropsychopharmacology. 2008;33:1942-1951.
27. Zhang F, Signore AP, Zhou Z, Wang S, Cao G, Chen J. Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms. J Neurosci Res. 2006;83:1241-1251.
28. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in frst-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-289.
29. Bahtiyar G, Weiss K, Sacerdote AS. Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocr Pract. 2007;13:601-608.
30. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Effcacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. 2011;32:1626-1633.
31. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics. 2008;5:481-489.
32. Association A P. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision. Washington, DC: Association AP; 2000.
33. Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull. 2007;33:21-32.
34. Holden C. Neuroscience. Deconstructing schizophrenia. Science. 2003;299:333-335.
35. Schwarz E, Izmailov R, Spain M, et al. Validation of a blood-based laboratory test to aid in the confrma-tion of a diagnosis of schizophrenia. Biomark Insights. 2010;5:39-47.
36. Di Nicola M, Cattaneo A, Hepgul N, et al. Serum and gene expression profle of cytokines in frst-episode psychosis. Brain Behav Immun. 2013;31:90-95.
37. Meltzer H Y, Sachar EJ, Frantz AG. Serum prolactin levels in unmedicated schizophrenic patients. Arch Gen Psychiatry. 1974;31:564-569.
38. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55-68.
39. Carter CJ. Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. Neurochem Int. 2007;50:461-490.
40. Ortiz-Domínguez A, Hernández ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9:596-602.
41. Schleifer SJ, Keller SE, Bond RN, Cohen J, Stein M. Major depressive disorder and immunity. Role of age, sex, severity, and hospitalization. Arch Gen Psychiatry. 1989;46:81-87.